Product Description
ACR-2316 is a novel, internally developed small molecule development candidate, rationally designed through advanced co-crystallography and the AP3 platform to achieve optimal target potency and selectivity delivering potent single agent anti-tumor activity across in vitro and in vivo preclinical studies, compared to benchmark WEE1 and PKMYT1 inhibitors. (Sourced from: https://ir.acrivon.com/news-releases/news-release-details/acrivon-therapeutics-announces-acr-2316-novel-dual-wee1-and)
Mechanisms of Action: PKMYT1 Inhibitor, WEE1 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Acrivon Therapeutics
Company Location: Eastern America
Company Founding Year: 2018
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
- Clinical Outcomes Reported - Acrivon Therapeutics presented P1 Oncology Solid Tumor Unspecified results on 2026-01-08 for ACR-2316
- Clinical Outcomes Expected - Acrivon Therapeutics announced they will present P1 Oncology Solid Tumor Unspecified results in 1Q26 for ACR-2316
- Clinical Outcomes Reported - Acrivon Therapeutics announced they will present P1 Oncology Solid Tumor Unspecified results in 4Q25 for ACR-2316
Highest Development Phases
Phase 1: Hereditary Sensory and Autonomic Neuropathies
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06667141 |
ACR-2316-101 | P1 |
Recruiting |
Hereditary Sensory and Autonomic Neuropathies |
2026-08-12 |
50% |
2026-01-13 |
Patient Enrollment|Primary Endpoints|Treatments |